Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS Pathways Hopes To Market its Psilocybin Capsule By 2025

COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.

Mushrooms_Brain
UK-Based group’s psilocybin therapy has fast track status • Source: Shutterstock

COMPASS Pathways believes it has found a viable, mind-altering therapy for treating long-term depression: a synthetic form of psilocybin now in Phase IIb trials which, if successful, could surmount current legal barriers and stigma associated with psychedelic substances, the company’s co-founder and chief innovation officer told Scrip.

A big step towards that goal was achieved this year in a placebo-controlled Phase I study evaluating COMP360 (psilocybin) in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category